Beam Therapeutics BEAM
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$11.08M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 49.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 23.60% to 25.25% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| ARK Investment Management LLC | Mutual Fund | 2026/Q3 | +1,570,510 | 11.8% |
| Baillie Gifford | Mutual Fund | 2026/Q3 | +508,732 | 0.8% |
| FMR | Mutual Fund | 2026/Q3 | +317,877 | 12.1% |
| Peregrine Investment Management, Inc. | Hedge Fund | 2026/Q3 | +239,030 | 0.3% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +169,793 | 0.3% |
| Public Sector Pension Investment Board | Government Pension Fund | 2026/Q3 | +154,000 | 0.2% |
| Edgestream Partners, L.P. | Hedge Fund | 2026/Q3 | +148,556 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +121,555 | 9.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +116,163 | 0.2% |
| Morgan Stanley | Public Company | 2026/Q3 | +1,186,149 | 1.7% |
| Contrarius Investment Management Ltd. | Mutual Fund | 2026/Q3 | +1,081,095 | 1.6% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +702,009 | 3.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +509,973 | 9.0% |
| FMR | Mutual Fund | 2026/Q3 | +441,216 | 11.8% |
| Jupiter Fund Management Plc | Mutual Fund | 2026/Q3 | +421,658 | 0.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 15 Oct 2026 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $23.98 | – |
| 15 Oct 2026 | John Evans | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $23.98 | 949,268 |
| 14 Oct 2026 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $23.57 | – |
| 30 Sep 2026 | Bethany Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | Automatic Disposition | -187 | $24.41 | 13,859 |
| 23 Sep 2026 | Giuseppe Ciaramella | President | Other Disposition | -123,407 | – | 165,161 |
| 26 Jul 2026 | Amy Simon | Chief Medical Officer | Automatic Disposition | -16,667 | $25.74 | 2,071 |
| 29 Jun 2026 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $34.31 | – |
| 29 Jun 2026 | Amy Simon | Chief Medical Officer | Automatic Disposition | -373 | $34.73 | 18,738 |
| 29 Jun 2026 | John Evans | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $35.91 | 949,267 |
| 28 Jun 2026 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $35.49 | – |
| 16 Jun 2026 | Giuseppe Ciaramella | President | Derivative Exercise and Retained | +35,505 | $1.03 | 165,161 |
| 2 Jun 2026 | John Michael Maraganore | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 2 Jun 2026 | Mark Fishman | Lead Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 2 Jun 2026 | Graham Cooper | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 2 Jun 2026 | Kathleen Walsh | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 2 Jun 2026 | Chirfi Guindo | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 2 Jun 2026 | Christi Shaw | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 | 19,676 |
| 13 Apr 2026 | Carole Ho | Former Independent Director | Intent to Sell (Form 144) | -87,784 | $30.73 | – |
| 1 Apr 2026 | Christine Bellon | Chief Legal Officer | Intent to Sell (Form 144) | -20,000 | $21.90 | – |
| 1 Apr 2026 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -66,874 | $21.90 | – |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 26,082,937 | 25.3% | 13.7 |
| 15 Oct 2026 | 26,243,605 | 25.4% | 14.1 |
| 30 Sep 2026 | 27,548,815 | 26.7% | 15.3 |
| 15 Sep 2026 | 25,884,796 | 25.1% | 12.6 |
| 31 Aug 2026 | 25,802,667 | 25.0% | 14.8 |
| 14 Aug 2026 | 24,374,054 | 23.6% | 16.1 |
No comments yet — be the first to weigh in on BEAM.
Sign in to join the discussion.